DexCom Future Growth
Future criteria checks 4/6
DexCom is forecast to grow earnings and revenue by 17.2% and 13.6% per annum respectively. EPS is expected to grow by 16.7% per annum. Return on equity is forecast to be 27.1% in 3 years.
Key information
17.2%
Earnings growth rate
16.7%
EPS growth rate
| Medical Equipment earnings growth | 17.2% |
| Revenue growth rate | 13.6% |
| Future return on equity | 27.1% |
| Analyst coverage | Good |
| Last updated | 26 Jul 2024 |
Recent future growth updates
Recent updates
Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?
Jul 26
DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures
Jul 26Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E
Jul 12DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact
Jul 03DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Jun 28Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Jun 03Dexcom: Positive Catalysts Ahead To Support Growth
May 13If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity
May 07DexCom: Attractive Discount After Strong Earnings Results
May 06Returns At DexCom (NASDAQ:DXCM) Are On The Way Up
Apr 25Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price
Apr 12DexCom Is Pricey For A Reason - Its Growth Story Reflects That
Apr 11Is DexCom (NASDAQ:DXCM) Using Too Much Debt?
Mar 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Mar 04DexCom: A Wealth Compounder In Healthcare
Feb 14DexCom: Stelo Stellar Outlook
Jan 17DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital
Jan 15DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing
Jan 01DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Dec 18A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Dec 05At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?
Nov 21DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital
Sep 28DexCom (NASDAQ:DXCM) Could Easily Take On More Debt
Sep 13Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Aug 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Aug 14DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet
Jun 05There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital
May 16Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?
Mar 21These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely
Mar 03DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price
Feb 13DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly
Nov 25Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)
Oct 21Dexcom launches G7 glucose monitoring system in parts of Europe, Asia
Oct 04What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?
Sep 24DexCom: A High-Priced Medical Devices Company Remains Stuck In A Downtrend
Sep 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5,510 | 1,038 | 1,101 | 1,514 | 19 |
| 12/31/2025 | 4,696 | 840 | 852 | 1,241 | 24 |
| 12/31/2024 | 4,013 | 668 | 658 | 1,038 | 21 |
| 6/30/2024 | 3,935 | 667 | 666 | 891 | N/A |
| 3/31/2024 | 3,802 | 639 | 584 | 802 | N/A |
| 12/31/2023 | 3,622 | 542 | 512 | 749 | N/A |
| 9/30/2023 | 3,403 | 377 | 500 | 747 | N/A |
| 6/30/2023 | 3,198 | 358 | 466 | 771 | N/A |
| 3/31/2023 | 3,023 | 293 | 416 | 754 | N/A |
| 12/31/2022 | 2,910 | 341 | 305 | 670 | N/A |
| 9/30/2022 | 2,793 | 244 | 261 | 643 | N/A |
| 6/30/2022 | 2,673 | 230 | 216 | 597 | N/A |
| 3/31/2022 | 2,572 | 258 | 95 | 486 | N/A |
| 12/31/2021 | 2,449 | 217 | 53 | 443 | N/A |
| 9/30/2021 | 2,319 | 577 | 140 | 509 | N/A |
| 6/30/2021 | 2,170 | 562 | 101 | 409 | N/A |
| 3/31/2021 | 2,027 | 530 | 236 | 502 | N/A |
| 12/31/2020 | 1,927 | 550 | 277 | 476 | N/A |
| 9/30/2020 | 1,821 | 231 | 264 | 447 | N/A |
| 6/30/2020 | 1,716 | 205 | 209 | 394 | N/A |
| 3/31/2020 | 1,601 | 148 | 131 | 305 | N/A |
| 12/31/2019 | 1,476 | 101 | 135 | 315 | N/A |
| 9/30/2019 | 1,351 | -171 | 51 | 205 | N/A |
| 6/30/2019 | 1,222 | -170 | 39 | 167 | N/A |
| 3/31/2019 | 1,128 | -130 | 53 | 144 | N/A |
| 12/31/2018 | 1,032 | -127 | 56 | 123 | N/A |
| 9/30/2018 | 915 | 43 | 64 | 131 | N/A |
| 6/30/2018 | 833 | -5 | 53 | 110 | N/A |
| 3/31/2018 | 761 | -33 | N/A | 83 | N/A |
| 12/31/2017 | 719 | -50 | N/A | 92 | N/A |
| 9/30/2017 | 669 | -48 | N/A | 64 | N/A |
| 6/30/2017 | 633 | -65 | N/A | 51 | N/A |
| 3/31/2017 | 599 | -88 | N/A | 57 | N/A |
| 12/31/2016 | 573 | -66 | N/A | 56 | N/A |
| 9/30/2016 | 533 | -57 | N/A | 54 | N/A |
| 6/30/2016 | 490 | -80 | N/A | 49 | N/A |
| 3/31/2016 | 445 | -64 | N/A | 45 | N/A |
| 12/31/2015 | 402 | -58 | N/A | 49 | N/A |
| 9/30/2015 | 356 | -58 | N/A | 46 | N/A |
| 6/30/2015 | 319 | -20 | N/A | 40 | N/A |
| 3/31/2015 | 285 | -23 | N/A | 29 | N/A |
| 12/31/2014 | 259 | -22 | N/A | 24 | N/A |
| 9/30/2014 | 227 | -26 | N/A | 20 | N/A |
| 6/30/2014 | 201 | -27 | N/A | 10 | N/A |
| 3/31/2014 | 178 | -31 | N/A | 5 | N/A |
| 12/31/2013 | 160 | -30 | N/A | 2 | N/A |
| 9/30/2013 | 142 | -36 | N/A | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DXCM's forecast earnings growth (17.2% per year) is above the savings rate (2.4%).
Earnings vs Market: DXCM's earnings (17.2% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: DXCM's earnings are forecast to grow, but not significantly.
Revenue vs Market: DXCM's revenue (13.6% per year) is forecast to grow faster than the US market (8.5% per year).
High Growth Revenue: DXCM's revenue (13.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DXCM's Return on Equity is forecast to be high in 3 years time (27.1%)